Abstract
Atherosclerotic vulnerable plaques may cause acute cardiovascular events. Matrix metalloproteinase (MMP) plays an important role in the pathological process of high-risk plaques. It degrades the extracellular matrix of atherosclerotic plaque, thus making the fibrous cap thinner and the plaque more vulnerable, which lead to rupture. MMP inhibitors (MMPI) can specially bind MMP and inhibit its activity. Taking MMP as the target, nuclear medical imaging can identify and evaluate the unstable plaque in molecular level, and can also be used to explore the biological characteristics of plaque, as well as to monitor drug efficiency. This review summarizes the development of nuclide targeted MMPI in atherosclerotic plaque imaging. Key words: Plaque, atherosclerotic; Radionuclide imaging; Matrix metalloproteinases; Trends
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Nuclear Medicine and Molecular Imaging
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
